- Email: [email protected]
Impact on Overall Survival of Glandular Metastasis in Patients with Metastatic Clear Cell Renal Cell Carcinoma. on Behalf of the Renal Cross Channel Group
Annals of Oncology 25 (Supplement 4): iv280–iv304, 2014 doi:10.1093/annonc/mdu337.18
genitourinary tumours, non-prostate 825P
abstracts
G. Gravis1, B. Chanez2, L. Derosa3, B. Beuselinck4, B. Laguerre5, P. Barthelemy6, P.E. Brachet7, F. Joly Lobbedez8, B. Escudier9, G.D. Stewart10, D. Harrison11, A. Laird12, N. Vasudev13, C. Ralph13, J. Larkin14, H. Lote15, J. Walz16, J. Thomassin17, N. Salem18, J.M. Boher19 1 Medical Oncology, Paoli Calmettes, Marseille, FRANCE 2 Medical Oncology, Institut Paoli-Calmettes, Marseille, FRANCE 3 Medical Oncology, Institut Gustave Roussy, Villejuif, FRANCE 4 Medical Oncology, Leuven Cancer Institute, Leuven, BELGIUM 5 Medical Oncology, Centre Eugène Marquis, Rennes, FRANCE 6 Medical Oncology, Hôpital de Hautepierre, Strasbourg, FRANCE 7 Medical Oncology, Centre François Baclesse, Caen, FRANCE 8 Medical Oncology, Centre Francois Baclesse, Caen, FRANCE 9 Institut de Cancérologie Gustave Roussy, Villejuif, FRANCE 10 Department of Urology and Edinburgh Urological Cancer Group, Western General Hospital, Edinburgh, UK 11 School of Medicine, St. Andrew’s University, Edinburgh, UK 12 Urological Cancer Group, University of Edinburgh, Edinburgh, UK 13 Medical Oncology, St James’s Institute of Oncology, Leeds, UK 14 Department of Medicine, Royal Marsden Hospital, London, UK 15 Medical Oncology, Royal Marsden Hospital, London, UK 16 Urologic Oncology, Institut Paoli-Calmettes, Marseille, FRANCE 17 Biopathology, Institut Paoli-Calmettes, Marseille, FRANCE 18 Radiotherapy, Paoli Calmettes, Marseille, FRANCE 19 Bioinformatics, Institut Paoli-Calmettes, Marseille, FRANCE
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv286/2241541 by guest on 15 October 2018
IMPACT ON OVERALL SURVIVAL OF GLANDULAR METASTASIS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA. ON BEHALF OF THE RENAL CROSS CHANNEL GROUP
Aim: Glandular metastasis (GM) as defined by pancreas, breast, parotid, thyroid and contralateral adrenal metastasis are rare in clear cell renal cell carcinoma. We have performed a multicenter comparison of metastatic clear cell RCC (mRCC) with GM and non-GM to determine if GM impacts on overall survival (OS). Methods: Data were collected from mRCC pts with GM or non-GM at metastatic presentation. GM: pts with at least one GM with or without other sites. Non-GM: pts without GM at metastatic presentation. Pts were treated in 5 French, 1 Belgian and 3 UK centers between January 2004 and October 2013. Association between OS and site of metastasis was assessed using the log-rank test for univariate analysis and the chi-square test for multivariable Cox regression. Results: 188 GM and 453 non-GM mRCC pts were analyzed. The majority were male (70.2%), median age was 59y, with no difference between the GM and non-GM groups. Interval from diagnosis to metastasis was 25.7 months (mo) (0.03-272.8)for GM and 4.8 mo (0.03-334) for non-GM ( p < 0.001). 39% GM pts were MSKCC favorable risk compared with 23% non-GM pts ( p <0.0001) and 6.7% GM pts were MSKCC poor risk vs 16.7% non-GM. Fuhrman grade was I/II in 48.7% GM pts and 33.6% in the non-GM ( p = 0.005). Median follow-up was 82.4 mo (68.9-89.5). Median OS was 64.8 mo (52.7-86) for GM and 39.8 mo (34.8-46.1) for non-GM (HR = 1.66 [95% CI = 1.32-2.1], p < 0.001). Age (<60y vs >60y), delay between renal tumor and metastatic diagnosis, MSKCC risk group and GM or non-GM group were significant parameters in univariate OS analysis ( p < 0.001). In a multivariate analysis adjusted according to MSKCC risk group, GM status was a strong prognostic factor (HR = 0.76 [95% CI = 0.59-0.98], p < 0.035). Conclusions: This large retrospective study shows that the presence of at least one GM at metastatic presentation of clear cell mRCC was associated with a significantly longer OS compared to non-GM pts. The presence of GM vs non-GM disease was an independent prognostic factor for OS. Further translational studies will be performed on matched primary tumor and metastasis samples to assess molecular differences between GM and non-GM. Disclosure: All authors have declared no conflicts of interest.
genitourinary tumours, non-prostate 825P
abstracts
G. Gravis1, B. Chanez2, L. Derosa3, B. Beuselinck4, B. Laguerre5, P. Barthelemy6, P.E. Brachet7, F. Joly Lobbedez8, B. Escudier9, G.D. Stewart10, D. Harrison11, A. Laird12, N. Vasudev13, C. Ralph13, J. Larkin14, H. Lote15, J. Walz16, J. Thomassin17, N. Salem18, J.M. Boher19 1 Medical Oncology, Paoli Calmettes, Marseille, FRANCE 2 Medical Oncology, Institut Paoli-Calmettes, Marseille, FRANCE 3 Medical Oncology, Institut Gustave Roussy, Villejuif, FRANCE 4 Medical Oncology, Leuven Cancer Institute, Leuven, BELGIUM 5 Medical Oncology, Centre Eugène Marquis, Rennes, FRANCE 6 Medical Oncology, Hôpital de Hautepierre, Strasbourg, FRANCE 7 Medical Oncology, Centre François Baclesse, Caen, FRANCE 8 Medical Oncology, Centre Francois Baclesse, Caen, FRANCE 9 Institut de Cancérologie Gustave Roussy, Villejuif, FRANCE 10 Department of Urology and Edinburgh Urological Cancer Group, Western General Hospital, Edinburgh, UK 11 School of Medicine, St. Andrew’s University, Edinburgh, UK 12 Urological Cancer Group, University of Edinburgh, Edinburgh, UK 13 Medical Oncology, St James’s Institute of Oncology, Leeds, UK 14 Department of Medicine, Royal Marsden Hospital, London, UK 15 Medical Oncology, Royal Marsden Hospital, London, UK 16 Urologic Oncology, Institut Paoli-Calmettes, Marseille, FRANCE 17 Biopathology, Institut Paoli-Calmettes, Marseille, FRANCE 18 Radiotherapy, Paoli Calmettes, Marseille, FRANCE 19 Bioinformatics, Institut Paoli-Calmettes, Marseille, FRANCE
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv286/2241541 by guest on 15 October 2018
IMPACT ON OVERALL SURVIVAL OF GLANDULAR METASTASIS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA. ON BEHALF OF THE RENAL CROSS CHANNEL GROUP
Aim: Glandular metastasis (GM) as defined by pancreas, breast, parotid, thyroid and contralateral adrenal metastasis are rare in clear cell renal cell carcinoma. We have performed a multicenter comparison of metastatic clear cell RCC (mRCC) with GM and non-GM to determine if GM impacts on overall survival (OS). Methods: Data were collected from mRCC pts with GM or non-GM at metastatic presentation. GM: pts with at least one GM with or without other sites. Non-GM: pts without GM at metastatic presentation. Pts were treated in 5 French, 1 Belgian and 3 UK centers between January 2004 and October 2013. Association between OS and site of metastasis was assessed using the log-rank test for univariate analysis and the chi-square test for multivariable Cox regression. Results: 188 GM and 453 non-GM mRCC pts were analyzed. The majority were male (70.2%), median age was 59y, with no difference between the GM and non-GM groups. Interval from diagnosis to metastasis was 25.7 months (mo) (0.03-272.8)for GM and 4.8 mo (0.03-334) for non-GM ( p < 0.001). 39% GM pts were MSKCC favorable risk compared with 23% non-GM pts ( p <0.0001) and 6.7% GM pts were MSKCC poor risk vs 16.7% non-GM. Fuhrman grade was I/II in 48.7% GM pts and 33.6% in the non-GM ( p = 0.005). Median follow-up was 82.4 mo (68.9-89.5). Median OS was 64.8 mo (52.7-86) for GM and 39.8 mo (34.8-46.1) for non-GM (HR = 1.66 [95% CI = 1.32-2.1], p < 0.001). Age (<60y vs >60y), delay between renal tumor and metastatic diagnosis, MSKCC risk group and GM or non-GM group were significant parameters in univariate OS analysis ( p < 0.001). In a multivariate analysis adjusted according to MSKCC risk group, GM status was a strong prognostic factor (HR = 0.76 [95% CI = 0.59-0.98], p < 0.035). Conclusions: This large retrospective study shows that the presence of at least one GM at metastatic presentation of clear cell mRCC was associated with a significantly longer OS compared to non-GM pts. The presence of GM vs non-GM disease was an independent prognostic factor for OS. Further translational studies will be performed on matched primary tumor and metastasis samples to assess molecular differences between GM and non-GM. Disclosure: All authors have declared no conflicts of interest.